Drug intelligence / Profile preview

ProV-101

Development stage: Preclinical
Lead developer: Progeneer
Modality: Vaccines & Immunotherapeutics

Overview

ProV-101 is a prophylactic vaccine candidate being developed by Progeneer for the prevention of Respiratory Syncytial Virus (RSV) infection. The vaccine is designed to target specific RSV antigens to elicit a protective immune response. Currently in the discovery stage, ProV-101 is part of Progeneer's pipeline which also includes the ProLNG platform, a suite of novel TLR7/8 agonist adjuvants designed to enhance vaccine efficacy. The program aims to provide immunity against RSV, a common respiratory pathogen that can cause severe disease in infants and older adults.

Targets

RSV G (Respiratory syncytial virus attachment glycoprotein)

Beyond the preview

Go deeper on ProV-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProV-101.

Explore the full profile